In a recent article distributed to all UF Health faculty and employees, David S. Guzick, M.D., Ph.D., recognized the OneFlorida Clinical Research Consortium and its contribution to UF’s growing preeminence in the implementation of educational and research programs at UF Health.
“The state’s designation of the University of Florida as a preeminent university carries with it the opportunity, if not the responsibility, to provide leadership in the organization of educational and research programs that engage stakeholders from around our state,” wrote Guzick. “[The UF] CTSI is already partnering with FSU and University of Miami on research programs under the OneFlorida Clinical Research Consortium, the OneFlorida Cancer Control Alliance funded by the state, and UF Health-led statewide research initiatives in diabetes research, brain research, Alzheimer’s disease, and surgical care outcomes and quality, among others.”
Started in 2012 under the leadership of Betsy Shenkman, Ph.D., chair of the Department of Health Outcomes and Policy, and David Nelson, M.D., director of the UF Clinical and Translational Science Institute (CTSI), the OneFlorida Clinical Research Consortium continues to contribute to UF’s reputation as a leader in biomedical research and population health.
“We have the opportunity to build an enduring research infrastructure that can improve health care and educate minority faculty members throughout the state with the OneFlorida Clinical Research Consortium,” said Shenkman. “UF Health’s strategic initiatives align perfectly with these endeavors through a shared commitment to build research capacity and leverage research to improve health in Florida.”